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ABSTRACT
Introduction: Studies have shown that FTY720 has
inconsistent effects in kidney transplant recipients.
Several review articles on FTY720 have been published,
but most have focused on the mechanism of action of
FTY720. Therefore, this review aims to evaluate and
determine the beneficial and harmful effects of FTY720
therapy in kidney transplant recipients.
Methods and analysis: We electronically searched
the following databases: PubMed, Scopus, the Web of
Sciences, EMBASE, Cochrane databases and the
Cochrane Central Registry of Controlled Trials. Any
clinical, randomised controlled trials relating to FTY720
for treating kidney transplant recipients were included
without publication status or language restriction.
Study selection, data extraction and assessment of
study quality were performed independently by two
researchers. Data were synthesised by either the fixed
effects or the random effects model according to a
heterogeneity test. If the extracted data were suitable
for meta-analysis, STATA software was used to
combine the relative risks for dichotomous outcomes,
and the mean differences for continuous outcomes
with 95% CIs were measured. Death, loss of function
and incidence of acute kidney rejection were assessed
as the primary outcomes. Renal graft function,
malignancy, delayed graft function and infection were
evaluated as secondary outcomes.
Ethics/dissemination: This review does not require
formal ethics approval because the data are not
individualised. The resulting review article will be
submitted for publication in a peer-reviewed journal.
Trial registration number: CRD42015024648.
INTRODUCTION
Kidney transplantation is a cost-effective
treatment for patients with end-stage renal
disease. However, the immune response of
the host to the grafted tissue is a challenge
frequently encountered in organ
transplantation.1 2
Initial studies have shown that the recipi-
ent’s T cells may recognise allogenic antigens
via direct or indirect mechanisms.1 In the
case of direct recognition, intact major histo-
compatibility complex molecules, which
usually present with the donor’s self-antigens,
are highly expressed on antigen-presenting
cells (APCs), and may be directly recognised
by the recipient’s T cells without further pro-
cessing by host APCs. Unlike the direct
pathway, host APCs can capture and process
alloantigens and present the allopeptides to
self T cells in the indirect pathway.2
Alloreactive responses may result in acute or
chronic rejection.3 Therefore, many preven-
tion strategies have been used to boost graft
survival rates. Common maintenance
methods focus on the modulation or suppres-
sion of adaptive immune responses.4 The
most frequent procedure used to prevent
graft rejection is the application of immuno-
suppressants such as calcineurin inhibitors
(cyclosporine and tacrolimus), mTOR inhibi-
tors (rapamycin), mycophenolic acid and cor-
ticosteroids.5 Although cyclosporine and
tacrolimus have been shown to effectively
reduce episodes of acute graft rejection, the
risk of chronic transplant rejection remains
high.6 Many studies have shown that FTY720
is a promising immunosuppressive drug that
can be used to suppress initial and subse-
quent responses to renal grafts. However, the
effects of the drug are not fully understood.7
FTY720 is a derivative of ISP-1 (myriocin),
which is a fungal metabolite that is
Strengths and limitations of this study
▪ Data can be consistent, precise and reliable.
▪ Study findings may explain inconsistent reports
concerning the effect of FTY720 in kidney trans-
plant recipients.
▪ Sample size, methods for measuring outcomes
and study environments may affect our study.
▪ The different criteria for efficacy evaluation and
combination therapies may cause significant het-
erogeneity in this review.
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structurally analogous to sphingosine. It is a lipid chemo-
attractant found in body fluids such as blood and lymph.
FTY720 is an immunomodulating drug that extends allo-
graft survival in numerous models by inhibiting lympho-
cyte emigration from lymphoid organs.8 The results
from phase I and II clinical trials of FTY720 therapy
have been promising, and phase III clinical trials are
currently ongoing.9 The potential mechanism of action
of FTY720 is the downregulation of sphingosine-1-
hosphate receptor (S1PR). Activated lymphocytes
express high levels of S1PR, which binds to
sphingosine-1-phosphate (S1P) and causes egression of
lymphocytes from the lymph nodes and spleen. FTY720
binds to S1PR1 and reduces its cell surface expression.
Thus, it blocks T cell egression from lymphoid organs
and acts as an immunosuppressive drug.10
A large number of preclinical studies using animal
models have demonstrated the efficacy of FTY720 in
solid organ allograft survival prolongation alone or in
combination with cyclosporine.11 12
In the last decade, many de novo renal transplant reci-
pients have received FTY720 at doses of 2.5 or
5.0 mg/day. The doses were mostly combined with corti-
costeroids and cyclosporine or mycophenolate mofetil
(MMF). In most studies, the recipients were followed for
more than 12 months after transplantation.13–15
Phase I clinical studies in humans have revealed that
FTY720 at doses of 1.0 mg/day or higher significantly
reduced peripheral blood lymphocyte counts.16 Phase II
clinical trials have demonstrated the efficacy of FTY720 in
the prevention of acute rejection in renal transplant reci-
pients.15 In Europe and Australasia, phase III randomised
controlled trials (over 1 year) showed 2.5 mg FTY720 with
MMF significantly prevented renal acute rejection.
However, more instances of antibody-mediated rejection
and more episodes of biopsy-proven chronic rejection
were reported with 2.5 mg FTY720 than with 2 g MMF.17
In a multicentre, randomised, open-label renal trans-
plantation study for the evaluation of 2.5 mg FTY720
versus MMF in a combination regimen with tacrolimus
and corticosteroids, the incidence of treated biopsy-
proven acute rejection was 22.9% with FTY720 and
18.5% with MMF. These results showed that FTY720
combined with tacrolimus and steroids did not have a
significant therapeutic advantage over MMF for the pre-
vention of acute rejection in de novo renal transplant
recipients over a 1-year period.13 Comparison of data
from other phase II and phase III trials in another mul-
ticentre study showed that FTY720-based regimens have
no beneficial effects on the preservation of renal func-
tion in recipients at high risk for delayed graft function
(DGF) and no advantage in preventing acute
rejection.18
However, clinical trials have shown that FTY720 has
promising efficacy in preventing acute rejection in de
novo renal transplant recipients.15 17 In contrast, some
studies have reported that treatment with FTY720 alone
or in combination with conventional
immunosuppressants and steroids did not result in a sig-
nificant therapeutic advantage in preventing acute rejec-
tion in renal transplant recipients. In some cases, the
use of FTY720 led to an increase in acute antibody-
mediated rejection.14 18 These studies suggest that our
knowledge of the effect of FTY720 in preventing allo-
graft rejection and supporting renal graft survival is
incomplete and so a comprehensive and precise review
is required.
METHODS AND ANALYSIS
This protocol was written in accordance with the
PRISMA-P guidelines for systematic reviews.19
Inclusion criteria for study selection
Types of studies
All RCTs in which patients in either intervention or
control groups received FTY720 alone or in combination
with other immunomodulators were included without
restriction regarding time, language or publication type.
Types of participants
Adults and children who received a renal transplant
from a living or brain-dead donor and were prescribed
FTY720 alone or in combination with other immunomo-
dulators were included. Recipients of simultaneous trans-
plants were excluded from this review.
Types of interventions
Studies reporting any type of FTY720 administration
(oral, injection, etc), alone or in combination with any
other immunosuppressants and at any doses in renal
transplantation, were included in the review.
Comparative interventions, including placebo controls
and other conventional treatments, were also included.
Types of outcome measures
Primary outcomes
▸ Death
▸ Loss of function
▸ Incidence of acute kidney rejection (diagnosed by
clinical assessment, biopsy evaluation and steroid
resistance).
Secondary outcomes
▸ Assessment of renal graft function by glomerular filtra-
tion rate, cystatin C, neutrophil gelatinase-associated
lipocalin (NGAL) and other biomarkers of kidney
function
▸ Incidence of treatment-related adverse reactions (bio-
chemical, neurological, haematological, gastrointes-
tinal, etc)
▸ Incidence of onset of new diseases such as diabetes
▸ Incidence of malignancy
▸ Incidence of DGF
▸ Incidence of infection.
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Search methods for identifying studies
Electronic searches
We identified relevant RCTs, in any language, by con-
ducting a systematic search of the Web of Sciences,
MEDLINE, Scopus, and Cochrane databases, the
Cochrane Central Registry of Controlled Trials and the
Cochrane Renal Group’s specialised register (table 1).
Searching other resources
Hand searching to identify relevant clinical studies men-
tioned in reports of transplant meetings, conference
proceedings and abstracts was performed. We also
scanned the bibliographies of all retrieved trials and
other relevant publications, including reviews and meta
analysis paper references, for additional relevant articles.
Data collection and analysis
Selection of studies
Eligible studies were presented according to the
PRISMA 2009 Flow Diagram. Our group worked in
pairs. Two authors (RG and RF) independently screened
and reviewed articles to identify titles and available
abstracts. They also acquired the full text of any article
judged to be potentially eligible. The same review team
independently applied eligibility criteria to the full text
of potentially eligible articles. The reviewers resolved dis-
agreement by consensus; any remaining differences
were resolved through discussion with NT and RA.
Data extraction and management
Using standard extraction forms, two authors (RG and
RF) extracted data concerning participants, sample sizes,
duration of studies and of follow-up, study environment,
interventions, outcomes, results and methods to
measure outcomes. Some heterogeneity may have
occurred because of potential variations in sample sizes,
duration of study, interventions and methods used to
measure outcomes; these variations were discussed
among the authors. The authors of the trial were con-
tacted if data were missing or more information was
required. Studies reported in non-English language jour-
nals were translated before assessment.
Assessment of risk of bias in the included studies
Measuring the effect of treatment
Continuous data were expressed as mean differences
with 95% CIs. For dichotomous data, the risk ratio with
corresponding 95% CIs was used. For data measured
using similar scales with similar units, weighted mean
differences were used. Otherwise, the standardised
mean difference was used to analyse the extracted data.
Dealing with missing data
We attempted to contact the relevant authors if data
were missing. If were unable to obtain missing data or
information, the study was omitted from data synthesis.
Assessment of heterogeneity
We estimated the level of heterogeneity across the
studies using STATA software (V.12), the χ2 test for statis-
tical heterogeneity, and the I2 statistic in forest plots.
Values of I2 <25% were classified as low heterogeneity,
25–50% as moderate heterogeneity and >50% as large
heterogeneity (grades A, B and C, respectively).
Assessment of reporting biases
We used funnel plots to detect potential reporting bias
and small-study effects. Asymmetries for more than 10
studies were included in the meta-analysis using the
Egger method.20
Data synthesis
If the extracted data were suitable for meta-analysis,
STATA software was used to combine the relative risks
for dichotomous outcomes, and the mean differences
for continuous outcomes with 95% CIs were measured.
If we found no evidence of heterogeneity, we used the
fixed effect model; otherwise, we applied a random
effects model. If significant heterogeneity between
Table 1 Search strategy used for the PubMed database*
No. Search items
1 Fingolimod
2 FTY720
3 FTY-720
4 FTY 720
5 Gilenya
6 fingolimod hydrochloride
7 2-amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol
hydrochloride
8 sphingosine-1-phosphate receptor agonist
9 sphingosine-1-phosphate receptor modulator
10 sphingosine-1-phosphate receptor
11 1 OR 2–10
12 systematic
13 11 AND 12
14 Kidney transplantation
15 Renal transplantation
16 Renal transplantations
17 Transplantation, renal
18 Grafting, kidney
19 Kidney grafting
20 Transplantation, kidney
21 Kidney/transplantation
22 14 OR 15–21
23 11 AND 22
24 intervention
25 effectiveness
26 comparative
27 clinical trial
28 controlled
29 placebo
30 24 OR 25–29
31 23 AND 30
*This search strategy will be suitable for other electronic
databases.
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studies was found, we used subgroup analysis to identify
possible clinical or methodological causes and offered
appropriate explanations for the differences.
Subgroup analysis
We performed subgroup analysis for heterogeneity
caused by main factors such as sample sizes, methods
used to measure outcomes, study environments and
types of intervention. For example, types of interven-
tions were classified based on the use of FTY720 alone
or in combination with other immunomodulators.
Sensitivity analysis
We conducted a sensitivity analysis to validate the study
design, conclusions and sample size and to investigate
suspected funnel plot asymmetry.
Ethics and dissemination
Ethics approval was not required as we did not use
patient data in this systematic review. The resulting
review article was submitted for publication in a peer-
reviewed journal.
DISCUSSION
The results of some clinical trials have demonstrated
that FTY720 has promising efficacy for preventing acute
rejection in de novo renal transplant patients.15 21 22
The first phase IIA study of de novo renal transplant-
ation showed that the incidence of biopsy-confirmed
acute rejection at 3 months after kidney transplantation
was dose dependent. The rate of acute rejection at a
dose of 0.25 mg was twofold higher than that at 2.5 mg.
In addition, the incidence of the composite endpoint
(biopsy-confirmed acute rejection, graft loss or death)
was lower with 2.5 mg FTY720 compared to lower
doses.15 In another study, an FTY720 blood concentra-
tion of 4 ng/mL in the early weeks after transplantation
was associated with a decrease in the maximal lympho-
cyte count. This decrease was correlated with evidence
of rejection prophylaxis.21 The results of a 6-month,
double-blind study indicated that the composite end-
point occurred within 6 months in 24% of FTY720
patients and 39% of MMF patients. In addition, FTY720
was associated with lower creatinine clearance but a
higher incidence of bradycardia than MMF.22 On the
other hand, some studies have demonstrated that
FTY720 alone or in combination with conventional
immunosuppressants and steroids did not decrease
acute rejection in renal transplant recipients.17 18
Indeed, in some cases, FTY720 caused an increase in
acute antibody-mediated rejection. An exploratory,
1-year, multicentre study in de novo renal transplant
patients at risk for DGF suggested that there were no
apparent benefits with FTY720-based regimens (2.5 mg)
for the prevention of acute rejection and preservation of
renal function in renal transplant recipients at high risk
for DGF.18
A 1-year, randomised controlled trial in Europe and
Australasia reported that 2.5 mg FTY720 was associated
with more antibody-mediated rejection and more epi-
sodes of biopsy-proven chronic rejection than MMF.
These unfavourable outcomes indicate a limited effect
of FTY720 on B cells.17 Given these ambiguous and
inconclusive results, a comprehensive, objective and sys-
tematic review of the effects of FTY720 on graft survival
in renal transplant recipients was required. Therefore,
the main purpose of this review was to estimate the rela-
tive and absolute effects of FTY720 therapy in kidney
transplant recipients and determine its beneficial and
harmful effects on renal tissue graft outcome and sur-
vival. A minor objectives of this review was to determine
which conventional immunosuppressants have the great-
est synergy with FTY720 for the prevention of acute
rejection and renal tissue graft survival.
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